Author

A. Maia

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell signaling & trafficking· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cell type annotation· 1 Research Focus:host-pathogen & immune response· 1 Approach:statistical model· 1

Frequent Co-Authors

S. Wiemann· 2 shared A. Chatziioannou· 1 shared A. Koch· 1 shared C. Becki· 1 shared C. Thomssen· 1 shared D. Bethmann· 1 shared E. Espinet· 1 shared I. Binenbaum· 1 shared

Activity by Year

2020-2020 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

S. Wiemann

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Reprogramming of stromal fibroblasts by chemotherapy-induced secretion of IFNβ1 drives re-growth of breast cancer cells after treatment.

A. Maia, Z. Gu, A. Koch, R. Will, M. Schlesner, S. Wiemann

This study shows chemotherapy-induced IFNβ1 secretion by cancer cells reprograms stromal fibroblasts, promoting breast cancer recurrence through an anti-viral state and pro-inflammatory cytokine expression.

bioRxiv · Aug 5, 2020 · PreprintCancer Biology

Stromal NRG1 in luminal breast cancer defines pro-fibrotic and migratory cancer-associated fibroblasts

M. Berdiel, A. Maia, Z. Hristova, S. Borgoni, M. Vetter, S. Burmester, C. Becki, K. Abnaof, I. Binenbaum, D. Bethmann, A. Chatziioannou, M. Hasmann, C. Thomssen, E. Espinet, S. Wiemann

The paper identifies NRG1-expressing cancer-associated fibroblasts that promote fibrosis and migration through autocrine signaling, independent of HER3, and highlights HAS2 as a targetable molecule.

bioRxiv · Apr 6, 2020Cancer Biology